Home / Publications / Featured Publications / Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction

Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction

January 15, 2015

Cite this

Abstract

Clinical studies have revealed that genetic variations in metabotropic glutamate receptor 3 (mGlu₃) affect performance on cognitive tasks dependent upon the prefrontal cortex (PFC) and may be linked to psychiatric conditions such as schizophrenia, bipolar disorder, and addiction. We have performed a series of studies aimed at understanding how mGlu₃ influences PFC function and cognitive behaviors. In the present study, we found that activation of mGlu₃ can induce long-term depression in the mouse medial PFC (mPFC) in vitro. Furthermore, in vivo administration of a selective mGlu₃ negative allosteric modulator impaired learning in the mPFC-dependent fear extinction task. The results of these studies implicate mGlu₃ as a major regulator of PFC function and cognition. Additionally, potentiators of mGlu₃ may be useful in alleviating prefrontal impairments associated with several CNS disorders.

Published

PNAS

Funding Source

This work was supported by a grant from the National Institute of Neurological Disease and Stroke (NS031373) (to P.J.C.), a postdoctoral fellowship from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation (to A.G.W.), and a National Institutes of Health predoctoral Training Grant (T32 GM007628) (to C.J.W.).

Cited by

This article is cited by 51 publications

Dogra, S., Putnam, J., & Conn, P. J. (2022). Metabotropic glutamate receptor 3 as a potential therapeutic target for psychiatric and neurological disorders. Pharmacology, biochemistry, and behavior, 221, 173493. https://doi.org/10.1016/j.pbb.2022.173493
Veselinović, T., & Neuner, I. (2022). Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia. CNS drugs, 10.1007/s40263-022-00935-z. Advance online publication. https://doi.org/10.1007/s40263-022-00935-z
Luessen, D. J., & Conn, P. J. (2022). Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease. Pharmacological reviews, 74(3), 630–661. https://doi.org/10.1124/pharmrev.121.000540
Vermudez, S., Buch, A., Weiss, K., Gogliotti, R. G., & Niswender, C. M. (2022). Exploration of group II metabotropic glutamate receptor modulation in mouse models of Rett syndrome and MECP2 Duplication syndrome. Neuropharmacology, 209, 109022. https://doi.org/10.1016/j.neuropharm.2022.109022
Dogra, S., & Conn, P. J. (2022). Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia. Molecular pharmacology, 101(5), 275–285. https://doi.org/10.1124/molpharm.121.000460
Hall, J., & Bray, N. J. (2022). Schizophrenia Genomics: Convergence on Synaptic Development, Adult Synaptic Plasticity, or Both?. Biological psychiatry, 91(8), 709–717. https://doi.org/10.1016/j.biopsych.2021.10.018
Tyler, R. E., Bluitt, M. N., Engers, J. L., Lindsley, C. W., & Besheer, J. (2022). The effects of predator odor (TMT) exposure and mGlu3 NAM pretreatment on behavioral and NMDA receptor adaptations in the brain. Neuropharmacology, 207, 108943. https://doi.org/10.1016/j.neuropharm.2022.108943
Dogra, S., & Conn, P. J. (2021). Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders. Neuropharmacology, 196, 108687. https://doi.org/10.1016/j.neuropharm.2021.108687
Dogra, S., Stansley, B. J., Xiang, Z., Qian, W., Gogliotti, R. G., Nicoletti, F., Lindsley, C. W., Niswender, C. M., Joffe, M. E., & Conn, P. J. (2021). Activating mGlu3 Metabotropic Glutamate Receptors Rescues Schizophrenia-like Cognitive Deficits Through Metaplastic Adaptations Within the Hippocampus. Biological psychiatry, 90(6), 385–398. https://doi.org/10.1016/j.biopsych.2021.02.970
Ruan, H., & Yao, W. D. (2021). Loss of mGluR1-LTD following cocaine exposure accumulates Ca2+-permeable AMPA receptors and facilitates synaptic potentiation in the prefrontal cortex. Journal of neurogenetics, 35(4), 358–369. https://doi.org/10.1080/01677063.2021.1931180
Banks, M. I., Zahid, Z., Jones, N. T., Sultan, Z. W., & Wenthur, C. J. (2021). Catalysts for change: the cellular neurobiology of psychedelics. Molecular biology of the cell, 32(12), 1135–1144. https://doi.org/10.1091/mbc.E20-05-0340
Xiang, Z., Lv, X., Lin, X., O'Brien, D. E., Altman, M. K., Lindsley, C. W., Javitch, J. A., Niswender, C. M., & Conn, P. J. (2021). Input-specific regulation of glutamatergic synaptic transmission in the medial prefrontal cortex by mGlu2/mGlu4 receptor heterodimers. Science signaling, 14(677), eabd2319. https://doi.org/10.1126/scisignal.abd2319
Joffe, M. E., Santiago, C. I., Oliver, K. H., Maksymetz, J., Harris, N. A., Engers, J. L., Lindsley, C. W., Winder, D. G., & Conn, P. J. (2020). mGlu2 and mGlu3 Negative Allosteric Modulators Divergently Enhance Thalamocortical Transmission and Exert Rapid Antidepressant-like Effects. Neuron, 105(1), 46–59.e3. https://doi.org/10.1016/j.neuron.2019.09.044
Moran, S. P., Xiang, Z., Doyle, C. A., Maksymetz, J., Lv, X., Faltin, S., Fisher, N. M., Niswender, C. M., Rook, J. M., Lindsley, C. W., & Conn, P. J. (2019). Biased M1 receptor-positive allosteric modulators reveal role of phospholipase D in M1-dependent rodent cortical plasticity. Science signaling, 12(610), eaax2057. https://doi.org/10.1126/scisignal.aax2057
Sun, W., Li, J., Cui, S., Luo, L., Huang, P., Tang, C., & An, L. (2019). Sleep Deprivation Disrupts Acquisition of Contextual Fear Extinction by Affecting Circadian Oscillation of Hippocampal-Infralimbic proBDNF. eNeuro, 6(5), ENEURO.0165-19.2019. https://doi.org/10.1523/ENEURO.0165-19.2019
Maksymetz, J., Joffe, M. E., Moran, S. P., Stansley, B. J., Li, B., Temple, K., Engers, D. W., Lawrence, J. J., Lindsley, C. W., & Conn, P. J. (2019). M1 Muscarinic Receptors Modulate Fear-Related Inputs to the Prefrontal Cortex: Implications for Novel Treatments of Posttraumatic Stress Disorder. Biological psychiatry, 85(12), 989–1000. https://doi.org/10.1016/j.biopsych.2019.02.020
Joffe, M. E., Santiago, C. I., Engers, J. L., Lindsley, C. W., & Conn, P. J. (2019). Metabotropic glutamate receptor subtype 3 gates acute stress-induced dysregulation of amygdalo-cortical function. Molecular psychiatry, 24(6), 916–927. https://doi.org/10.1038/s41380-017-0015-z
Stansley, B. J., & Conn, P. J. (2019). Neuropharmacological Insight from Allosteric Modulation of mGlu Receptors. Trends in pharmacological sciences, 40(4), 240–252. https://doi.org/10.1016/j.tips.2019.02.006
Neale, J. H., & Olszewski, R. (2019). A role for N-acetylaspartylglutamate (NAAG) and mGluR3 in cognition. Neurobiology of learning and memory, 158, 9–13. https://doi.org/10.1016/j.nlm.2019.01.006
Joffe, M. E., Santiago, C. I., Stansley, B. J., Maksymetz, J., Gogliotti, R. G., Engers, J. L., Nicoletti, F., Lindsley, C. W., & Conn, P. J. (2019). Mechanisms underlying prelimbic prefrontal cortex mGlu3/mGlu5-dependent plasticity and reversal learning deficits following acute stress. Neuropharmacology, 144, 19–28. https://doi.org/10.1016/j.neuropharm.2018.10.013
de la Fuente Revenga, M., Ibi, D., Cuddy, T., Toneatti, R., Kurita, M., Ijaz, M. K., Miles, M. F., Wolstenholme, J. T., & González-Maeso, J. (2019). Chronic clozapine treatment restrains via HDAC2 the performance of mGlu2 receptor agonism in a rodent model of antipsychotic activity. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 44(2), 443–454. https://doi.org/10.1038/s41386-018-0143-4
Mazzitelli, M., Palazzo, E., Maione, S., & Neugebauer, V. (2018). Group II Metabotropic Glutamate Receptors: Role in Pain Mechanisms and Pain Modulation. Frontiers in molecular neuroscience, 11, 383. https://doi.org/10.3389/fnmol.2018.00383
Joffe, M. E., Centanni, S. W., Jaramillo, A. A., Winder, D. G., & Conn, P. J. (2018). Metabotropic Glutamate Receptors in Alcohol Use Disorder: Physiology, Plasticity, and Promising Pharmacotherapies. ACS chemical neuroscience, 9(9), 2188–2204. https://doi.org/10.1021/acschemneuro.8b00200
Hsu, T. M., Noble, E. E., Liu, C. M., Cortella, A. M., Konanur, V. R., Suarez, A. N., Reiner, D. J., Hahn, J. D., Hayes, M. R., & Kanoski, S. E. (2018). A hippocampus to prefrontal cortex neural pathway inhibits food motivation through glucagon-like peptide-1 signaling. Molecular psychiatry, 23(7), 1555–1565. https://doi.org/10.1038/mp.2017.91
O'Brien, D. E., Shaw, D. M., Cho, H. P., Cross, A. J., Wesolowski, S. S., Felts, A. S., Bergare, J., Elmore, C. S., Lindsley, C. W., Niswender, C. M., & Conn, P. J. (2018). Differential Pharmacology and Binding of mGlu2 Receptor Allosteric Modulators. Molecular pharmacology, 93(5), 526–540. https://doi.org/10.1124/mol.117.110114
Ting, J. T., Lee, B. R., Chong, P., Soler-Llavina, G., Cobbs, C., Koch, C., Zeng, H., & Lein, E. (2018). Preparation of Acute Brain Slices Using an Optimized N-Methyl-D-glucamine Protective Recovery Method. Journal of visualized experiments : JoVE, (132), 53825. https://doi.org/10.3791/53825
Ershov, N. I., Bondar, N. P., Lepeshko, A. A., Reshetnikov, V. V., Ryabushkina, J. A., & Merkulova, T. I. (2018). Consequences of early life stress on genomic landscape of H3K4me3 in prefrontal cortex of adult mice. BMC genomics, 19(Suppl 3), 93. https://doi.org/10.1186/s12864-018-4479-2
Stansley, B. J., & Conn, P. J. (2018). The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia. Current opinion in pharmacology, 38, 31–36. https://doi.org/10.1016/j.coph.2018.02.003
Di Menna, L., Joffe, M. E., Iacovelli, L., Orlando, R., Lindsley, C. W., Mairesse, J., Gressèns, P., Cannella, M., Caraci, F., Copani, A., Bruno, V., Battaglia, G., Conn, P. J., & Nicoletti, F. (2018). Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system. Neuropharmacology, 128, 301–313. https://doi.org/10.1016/j.neuropharm.2017.10.026
Walker, A. G., Sheffler, D. J., Lewis, A. S., Dickerson, J. W., Foster, D. J., Senter, R. K., Moehle, M. S., Lv, X., Stansley, B. J., Xiang, Z., Rook, J. M., Emmitte, K. A., Lindsley, C. W., & Conn, P. J. (2017). Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP and Long-Term Potentiation, and Disrupts Memory Reconsolidation. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 42(13), 2553–2566. https://doi.org/10.1038/npp.2017.136
Engers, J. L., Bollinger, K. A., Weiner, R. L., Rodriguez, A. L., Long, M. F., Breiner, M. M., Chang, S., Bollinger, S. R., Bubser, M., Jones, C. K., Morrison, R. D., Bridges, T. M., Blobaum, A. L., Niswender, C. M., Conn, P. J., Emmitte, K. A., & Lindsley, C. W. (2017). Design and Synthesis of N-Aryl Phenoxyethoxy Pyridinones as Highly Selective and CNS Penetrant mGlu3 NAMs. ACS medicinal chemistry letters, 8(9), 925–930. https://doi.org/10.1021/acsmedchemlett.7b00249
Bollinger, K. A., Felts, A. S., Brassard, C. J., Engers, J. L., Rodriguez, A. L., Weiner, R. L., Cho, H. P., Chang, S., Bubser, M., Jones, C. K., Blobaum, A. L., Niswender, C. M., Conn, P. J., Emmitte, K. A., & Lindsley, C. W. (2017). Design and Synthesis of mGlu2 NAMs with Improved Potency and CNS Penetration Based on a Truncated Picolinamide Core. ACS medicinal chemistry letters, 8(9), 919–924. https://doi.org/10.1021/acsmedchemlett.7b00279
McColm, J., Brittain, C., Suriyapperuma, S., Swanson, S., Tauscher-Wisniewski, S., Foster, J., Soon, D., & Jackson, K. (2017). Evaluation of single and multiple doses of a novel mGlu2 agonist, a potential antipsychotic therapy, in healthy subjects. British journal of clinical pharmacology, 83(8), 1654–1667. https://doi.org/10.1111/bcp.13252
Foster, D. J., & Conn, P. J. (2017). Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders. Neuron, 94(3), 431–446. https://doi.org/10.1016/j.neuron.2017.03.016
Johnson, K. A., Mateo, Y., & Lovinger, D. M. (2017). Metabotropic glutamate receptor 2 inhibits thalamically-driven glutamate and dopamine release in the dorsal striatum. Neuropharmacology, 117, 114–123. https://doi.org/10.1016/j.neuropharm.2017.01.038
Le Hellard, S., Wang, Y., Witoelar, A., Zuber, V., Bettella, F., Hugdahl, K., Espeseth, T., Steen, V. M., Melle, I., Desikan, R., Schork, A. J., Thompson, W. K., Dale, A. M., Djurovic, S., Andreassen, O. A., & Schizophrenia Working Group of the Psychiatric Genomics Consortium (2017). Identification of Gene Loci That Overlap Between Schizophrenia and Educational Attainment. Schizophrenia bulletin, 43(3), 654–664. https://doi.org/10.1093/schbul/sbw085
Maksymetz, J., Moran, S. P., & Conn, P. J. (2017). Targeting metabotropic glutamate receptors for novel treatments of schizophrenia. Molecular brain, 10(1), 15. https://doi.org/10.1186/s13041-017-0293-z
Liu, W., Ge, T., Leng, Y., Pan, Z., Fan, J., Yang, W., & Cui, R. (2017). The Role of Neural Plasticity in Depression: From Hippocampus to Prefrontal Cortex. Neural plasticity, 2017, 6871089. https://doi.org/10.1155/2017/6871089
Johnson, K. A., & Lovinger, D. M. (2016). Presynaptic G Protein-Coupled Receptors: Gatekeepers of Addiction?. Frontiers in cellular neuroscience, 10, 264. https://doi.org/10.3389/fncel.2016.00264
Kang, S. J., & Kaang, B. K. (2016). Metabotropic glutamate receptor dependent long-term depression in the cortex. The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology, 20(6), 557–564. https://doi.org/10.4196/kjpp.2016.20.6.557
Samarasinghe, K. T., Munkanatta Godage, D. N., Zhou, Y., Ndombera, F. T., Weerapana, E., & Ahn, Y. H. (2016). A clickable glutathione approach for identification of protein glutathionylation in response to glucose metabolism. Molecular bioSystems, 12(8), 2471–2480. https://doi.org/10.1039/c6mb00175k
Lindsley, C. W., Emmitte, K. A., Hopkins, C. R., Bridges, T. M., Gregory, K. J., Niswender, C. M., & Conn, P. J. (2016). Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors. Chemical reviews, 116(11), 6707–6741. https://doi.org/10.1021/acs.chemrev.5b00656
Muguruza, C., Meana, J. J., & Callado, L. F. (2016). Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs. Frontiers in pharmacology, 7, 130. https://doi.org/10.3389/fphar.2016.00130
O'Brien, D. E., & Conn, P. J. (2016). Neurobiological Insights from mGlu Receptor Allosteric Modulation. The international journal of neuropsychopharmacology, 19(5), pyv133. https://doi.org/10.1093/ijnp/pyv133
Senter, R. K., Ghoshal, A., Walker, A. G., Xiang, Z., Niswender, C. M., & Conn, P. J. (2016). The Role of mGlu Receptors in Hippocampal Plasticity Deficits in Neurological and Psychiatric Disorders: Implications for Allosteric Modulators as Novel Therapeutic Strategies. Current neuropharmacology, 14(5), 455–473. https://doi.org/10.2174/1570159x13666150421003225
Balu D. T. (2016). The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment. Advances in pharmacology (San Diego, Calif.), 76, 351–382. https://doi.org/10.1016/bs.apha.2016.01.006
Ghoshal, A., Rook, J. M., Dickerson, J. W., Roop, G. N., Morrison, R. D., Jalan-Sakrikar, N., Lamsal, A., Noetzel, M. J., Poslusney, M. S., Wood, M. R., Melancon, B. J., Stauffer, S. R., Xiang, Z., Daniels, J. S., Niswender, C. M., Jones, C. K., Lindsley, C. W., & Conn, P. J. (2016). Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 41(2), 598–610. https://doi.org/10.1038/npp.2015.189
Felts, A. S., Rodriguez, A. L., Smith, K. A., Engers, J. L., Morrison, R. D., Byers, F. W., Blobaum, A. L., Locuson, C. W., Chang, S., Venable, D. F., Niswender, C. M., Daniels, J. S., Conn, P. J., Lindsley, C. W., & Emmitte, K. A. (2015). Design of 4-Oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides as Selective Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 2. Journal of medicinal chemistry, 58(22), 9027–9040. https://doi.org/10.1021/acs.jmedchem.5b01371
Engers, J. L., Rodriguez, A. L., Konkol, L. C., Morrison, R. D., Thompson, A. D., Byers, F. W., Blobaum, A. L., Chang, S., Venable, D. F., Loch, M. T., Niswender, C. M., Daniels, J. S., Jones, C. K., Conn, P. J., Lindsley, C. W., & Emmitte, K. A. (2015). Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents. Journal of medicinal chemistry, 58(18), 7485–7500. https://doi.org/10.1021/acs.jmedchem.5b01005
Kiritoshi, T., & Neugebauer, V. (2015). Group II mGluRs modulate baseline and arthritis pain-related synaptic transmission in the rat medial prefrontal cortex. Neuropharmacology, 95, 388–394. https://doi.org/10.1016/j.neuropharm.2015.04.003
Ellaithy, A., Younkin, J., González-Maeso, J., & Logothetis, D. E. (2015). Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment. Trends in neurosciences, 38(8), 506–516. https://doi.org/10.1016/j.tins.2015.06.002